International Journal of Hematology

, Volume 98, Issue 3, pp 361–365 | Cite as

Nilotinib-induced interstitial lung disease

  • Se-Il Go
  • Won Sup Lee
  • Gyeong-Won Lee
  • Jung Hun Kang
  • Myung Hee Kang
  • Jeong-Hee Lee
  • Hoon-Gu Kim
Case Report

Abstract

Nilotinib is a second-generation tyrosine kinase inhibitor active in patients with chronic myeloid leukemia (CML) resistant to imatinib, and has been recently approved for newly diagnosed patients. We present a case of nilotinib-induced interstitial lung disease (ILD). A 67-year-old female patient was initially treated with imatinib for chronic-phase Philadelphia chromosome-positive (Ph+) CML. Imatinib was replaced by nilotinib because of hematological toxicity. The patient had received nilotinib for about 3 years without significant adverse effects. She visited the clinic due to chronic cough; chest X-ray revealed consolidations in both lung fields. Nilotinib-induced ILD was diagnosed based on intensive workup, including lung biopsy. She responded dramatically to corticosteroid therapy. To our knowledge, this is the first reported case of nilotinib-induced ILD in a patient with Ph+ CML. We emphasize that if unexplained lung abnormalities progress in patients receiving nilotinib, physicians should consider this potentially fatal complication in their differential diagnoses.

Keywords

Nilotinib Chronic myeloid leukemia Interstitial lung disease 

References

  1. 1.
    Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176:814–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Radaelli F, Bramanti S, Fantini NN, Fabio G, Greco I, Lambertenghi-Deliliers G. Dasatinib-related alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma. 2006;47:1180–1.PubMedCrossRefGoogle Scholar
  6. 6.
    Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009;3:89–101.PubMedGoogle Scholar
  9. 9.
    Delomas T, Darne C, Besson C. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leuk Lymphoma. 2012;53:332–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20:1162–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003;78:1578–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3, imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol. 2003;21:3171–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration. 2008;75:350–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Rajda J, Phatak PD. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am J Hematol. 2005;79:80–1.PubMedCrossRefGoogle Scholar
  17. 17.
    Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinib-associated pulmonary alveolar proteinosis. Am J Med. 2003;115:674.PubMedCrossRefGoogle Scholar
  18. 18.
    Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20:4271–2.PubMedCrossRefGoogle Scholar
  19. 19.
    Lin JT, Yeh KT, Fang HY, Chang CS. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma. 2006;47:1693–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Grimison P, Goldstein D, Schneeweiss J, Murray N. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms. Intern Med J. 2005;35:136–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Izumiyama N, Noguchi K, Takahashi H, Shishikura Y, Saitou W, Nishimaki K, et al. Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST). Nihon Kokyuki Gakkai Zasshi. 2009;47:918–23.PubMedGoogle Scholar
  22. 22.
    Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71:301–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95:90–5.PubMedGoogle Scholar
  24. 24.
    Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, et al. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica. 2008;93:1918–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93–113.PubMedCrossRefGoogle Scholar
  26. 26.
    Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia. 2004;18:645–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest. 1991;88:663–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Walsh J, Absher M, Kelley J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol. 1993;9:637–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Dao K, Vedy D, Lopez J, Staneczek O, Buclin T, Livio F. Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. Int J Hematol. 2013;97:299–300.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Se-Il Go
    • 1
  • Won Sup Lee
    • 1
  • Gyeong-Won Lee
    • 1
  • Jung Hun Kang
    • 1
  • Myung Hee Kang
    • 1
  • Jeong-Hee Lee
    • 2
  • Hoon-Gu Kim
    • 1
  1. 1.Division of Hematology-Oncology, Department of Internal Medicine, Gyeongnam Regional Cancer CenterInstitute of Health Sciences, Gyeongsang National University School of MedicineJinjuKorea
  2. 2.Department of Pathology, Institute of Health SciencesGyeongsang National University School of MedicineJinjuKorea

Personalised recommendations